CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 256 enrolled
Drug / intervention
Cladribinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04934800
NCT04934800N/ACompleted
CompareCT.gov

Oral CLADribine in Patients That Change From First-line Disease Modifying Treatments for Multiple Sclerosis: a pROspective effectivenesS and Safety Study (CLAD CROSS)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·observational·Posted Jun 22, 2021·Updated Jun 24, 2025

In Brief

An observational study evaluating Cladribine for Multiple Sclerosis. Completed, enrolled 256 participants across 61 sites in 7 countries.

Detailed Summary

The main aim was to study in the real world setting the effectiveness of Cladribine tablets in terms of Annualized Relapse Rate (ARR) and disability progression, in participants who switched from a first line Disease Modifying Drug (DMD) (Interferons, Glatiramer Acetate, Teriflunomide, (Dymethyl fumarate) \[DMF\]) to treatment with Cladribine tablets in routine clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesAustria, Greece, Italy, Norway, Poland, Portugal, Switzerland
CollaboratorsMerck Hellas sa., Greece, an affiliate of Merck KGaA, Darmstadt, Germany

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJun 22, 2021
Enrollment StartDec 10, 2019
Primary CompletionMay 20, 2024
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 5.0 years ago

Interventions

Cladribinedrug

No intervention will be administered as a part of this study. Participants who had switched from first-line DMD treatments to treatment with cladribine tablets in routine clinical practice will be assessed for 2 years in this study.